English
中文简体
中文繁体
Company
Overview
Management
SAB
Board of Directors
Partnering
Technology
Bispecific
Mix-mAb
Biologics Manufacturing
Publications
Pipeline
Overview
KN035
KN046
KN026
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
IR Contacts
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Management
SAB
Board of Directors
Partnering
Technology
Bispecific
Mix-mAb
Biologics Manufacturing
Publications
Pipeline
Overview
KN035
KN046
KN026
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
IR Contacts
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
Investors
Information Disclosure
Listing Documents
Financial Reports
Announcements & Circulars
Company Presentation
Corporate Governance
Stock Information
IR Contacts
Email Subscription
Announcements & Circulars
The announcement begins in December 2019
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2020
2020-07-03
INSIDE INFORMATION ANNOUNCEMENT - COMPLETION OF PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDER
2020-06-16
INSIDE INFORMATION ANNOUNCEMENT - PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDER
2020-06-12
VOLUNTARY ANNOUNCEMENT - CO-DEVELOPMENT OF ANTIBODY FOR CORONAVIRUS TREATMENT WITH INSTITUT PASTEUR OF SHANGHAI
2020-06-10
VOLUNTARY ANNOUNCEMENT - STRATEGIC COLLABORATION WITH SANOFI ON KN026 IN HER2+ BREAST CANCER
2020-06-09
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2020
2020-06-02
VOLUNTARY ANNOUNCEMENT - COLLABORATION AGREEMENT OF ANTI-TUMOR COMBINATION THERAPY WITH SLP
2020-05-28
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON MAY 25, 2020
2020-05-25
Next Day Disclosure Return
2020-05-21
VOLUNTARY ANNOUNCEMENT - ABSTRACTS ON USING TRANSLATIONAL TGI MODEL AND POPULATION PK ANALYSIS FOR KN026 ACCEPTED FOR POSTER PRESENTATION AT 2020 AACR ANNUAL MEETING
2020-05-18
ABSTRACTS ON PRELIMINARY RESULTS FROM CLINICAL TRIALS OF KN035 ACCEPTED FOR POSTER PRESENTATION AT 2020 ASCO ANNUAL MEETING
2020-05-15
VOLUNTARY ANNOUNCEMENT - ABSTRACTS ON PRELIMINARY RESULTS FROM CLINICAL TRIALS OF KN026 AND KN046 ACCEPTED FOR POSTER PRESENTATION AT 2020 ASCO ANNUAL MEETING
2020-05-14
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2020
2020-05-06
2019 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
2020-04-22
NOTICE OF ANNUAL GENERAL MEETING
2020-04-21
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING
2020-04-21
(1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED ADOPTION OF POST-IPO SHARE OPTION SCHEME; (3) PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS; (4) PROPOSED RE-APPOINTMENT OF AUDITORS; AND(5) NOTICE OF ANNUAL GENERAL MEETING
2020-04-21
2019 Annual Report
2020-04-21
VOLUNTARY ANNOUNCEMENT - JIANGSU ALPHAMAB RECEIVED THE SAFE TO PROCEED LETTER FROM THE U.S. FDA FOR A PHASE II CLINICAL TRIAL OF KN046 FOR NSCLC IN THE UNITED STATES
2020-04-15
ADOPTION OF POST-IPO SHARE OPTION SCHEME
2020-04-14
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2020
2020-04-03
CONNECTED TRANSACTION ANNOUNCEMENT - TECHNOLOGY DEVELOPMENT AGREEMENT WITH SUZHOU ALPHAMAB ON PROCESS OPTIMIZATION AND TRANSFER OF KN019, KN026 AND KN035 AND TECHNOLOGY DEVELOPMENT AGREEMENT WITH SUZHOU ALPHAMAB ON PROCESS SCALE-UP RESEARCH OF KN052
2020-03-31
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2019
2020-03-31
INSIDE INFORMATION ANNOUNCEMENT - COLLABORATIVE AGREEMENT WITH SIMCERE PHARMACEUTICAL AND 3D MEDICINES FOR KN035 AND SUPPLEMENTAL AGREEMENTS TO THE KN035 CO-DEVELOPMENT AGREEMENT
2020-03-30
VOLUNTARY ANNOUNCEMENT - COLLABORATION WITH PFIZER ON KN026 IN COMBINATION WITH IBRANCE(PALBOCICLIB) IN HER2+ BREAST CANCER
2020-03-27
DATE OF BOARD MEETING
2020-03-18
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2020
2020-03-04
VOLUNTARY ANNOUNCEMENT - FOUR IND APPLICATIONS ACCEPTED BY NMPA CDE FOR TWO ANTI-TUMOR BISEPECIFIC ANTIBODIES IN PIPELINE
2020-02-20
VOLUNTARY ANNOUNCEMENT - JIANGSU ALPHAMAB PASSED ON-SITE INSPECTION OF EU QUALIFIED PERSON
2020-02-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2020
2020-02-05
Next Day Disclosure Return
2020-01-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2019
2020-01-06
FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD
2020-01-05
INSIDE INFORMATION ANNOUNCEMENT – COLLABORATIVE PARTNERSHIP AGREEMENT WITH TRACON AND 3DMED
2019-12-20
VOLUNTARY ANNOUNCEMENT - COMPLETION OF CONSTRUCTION OF THE PHASE I MANUFACTURING FACILITIES
2019-12-18
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE II CLINICAL TRIAL OF KN019 FOR RHEUMATOID ARTHRITIS TREATMENT IN CHINA
2019-12-16
Terms of Reference of the Strategy Committee
2019-12-11
Terms of Reference of the Remuneration Committee
2019-12-11
Terms of Reference of the Audit Committee
2019-12-11
Terms of Reference of the Nomination Committee
2019-12-11
Amended and Restated Memorandum of Association
2019-12-11
List of Directors and their Role and Function
2019-12-11
Announcement of Offer Price and Allotment Results
2019-12-11
Global Offering-Formal Notice
2019-12-02
